Earnings Call · Q4 FY2021·2022-03-08

Q4 21EPS +100.00%*·Rev n/aQ3 21EPS +8.22%·Rev n/aQ2 21EPS -17.65%·Rev n/aQ1 21EPS +12.12%·Rev n/a⚠ consensus missing

Voyager Therapeutics, Inc. VYGR

Julie Burek — Vice President of Finance

Michael Higgins — Chief Executive Officer

Allen Nunnally — Chief Business Officer

Glenn Pierce — Chief Scientific Officer

+33.3%1d on move date+34.1% vs SPY3d+58.3%5d+57.8%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more VYGR calls or request research access.

More VYGR calls Browse calls Request research access